Conditions: Paget's Disease of the Bone
Keywords: Paget's Disease Zoledronic acid Reclast®/Aclasta® Infusion Re-treatment Re-lapse
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 6
Healthy volunteers: no

Brief summary:
The purpose of this study was to demonstrate that participants with Paget's disease of the bone who had responded to zoledronic acid treatment as participants in the core registration studies CZOL446K2304 and CZOL446K2305 and later experienced a relapse can be successfully treated with a 5 milligram (mg) infusion of zoledronic acid.

Detailed description:
Uncontrolled study

Arms:
arm 1: Participants received single re-treatment dose of zoledronic acid 5 mg intravenous (IV) infusion.

Interventions: intervention 1: Zoledronic Acid
Intervention descriptions: intervention 1: Zoledronic acid 5 mg intravenous infusion once

Protocol document: